Phospho-Smad3L promotes progression of hepatocellular carcinoma through decreasing miR-140-5p level and stimulating epithelial-mesenchymal transition

被引:6
|
作者
Hu, Xiangpeng [1 ,2 ]
Han, Dan [3 ,4 ]
Wang, Yanyan [3 ,4 ]
Gu, Jiong [5 ]
Wang, Xian [6 ]
Jiang, Yufeng [2 ]
Yang, Yan [2 ]
Liu, Jun [3 ,4 ,7 ]
机构
[1] Anhui Med Univ, Affiliated Hosp 2, Digest Dept, Hefei, Peoples R China
[2] Anhui Med Univ, Sch Basic Med Coll, Dept Pharmacol, Hefei, Peoples R China
[3] Anhui Med Univ, Sch Basic Med Coll, Dept Pathophysiol, Hefei, Peoples R China
[4] Anhui Med Univ, Biopharmaceut Res Inst, Hefei, Peoples R China
[5] Anhui Med Univ, Affiliated Hosp 2, Dept Gen Surg, Hefei, Peoples R China
[6] Anhui Med Univ, Affiliated Hosp 2, Dept Pathol, Hefei, Peoples R China
[7] Anhui Med Univ, Sch Basic Med Coll, Funct Expt Ctr, Hefei, Peoples R China
关键词
Linker-phosphorylated Smad3; Hepatocellular carcinoma; MircoRNA-140-5p; Epithelial-mesenchymal transition; TGF-BETA; TUMOR-SUPPRESSION; P38; MAPK; GROWTH; ONCOGENESIS; JNK;
D O I
10.1016/j.dld.2021.03.003
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: The transforming growth factor beta (TGF-beta) activates JNK, phosphorylates Smad3 to linkerphosphorylated Smad3 (pSmad3L), resulting in liver tumorigenesis. However, the effect of pSmad3L on hepatocellular carcinoma (HCC) prognosis is obscure. Aim: To detect the effect of pSmad3L on HCC prognosis and investigate the mechanism. Methods: The expressions of pSmad3L, E-cadherin, vimentin and MicroRNA-140-5p (miR-140-5p) were detected by using immunohistochemistry, immunofluorescence and in situ hybridization. Next, the relationships of pSmad3L and HCC patients' prognoses, pSmad3L and EMT markers, pSmad3L and miR-140-5p were analyzed using Spearman's rank correlation test. JNK/pSmad3L specific inhibitor SP600125 or Smad3 mutant plasmid was used to suppress JNK/pSmad3L pathway, and QPCR assay was performed to investigate the effect of pSmad3L on miR-140-5p level. The proliferation and invasion of hepatoma cells were observed using colony formation assay and transwell assay. Results: We demonstrated that patient with high level of pSmad3L predicted poor prognosis. Next, we verified that pSmad3L promoted EMT of hepatoma cells in vivo and in vitro . In order to investigate the mechanism, we verified a negative correlation between pSmad3L and miR-140-5p, which was an EMT inhibitor, in the liver tissues of HCC patient and diethylnitrosamine (DEN)-induced rat HCC model. We further used SP600125 or pSmad3L mutant plasmid to decrease pSmad3L level of hepatoma cells, and inhibition of pSmad3L increased miR-140-5p level and suppressed EMT of hepatoma cells. Conclusions: JNK/pSmad3L pathway induces EMT by inhibiting miR-140-5p in HCC progression. (C) 2021 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:1343 / 1351
页数:9
相关论文
共 50 条
  • [21] LncSNHG3 promotes hepatocellular carcinoma epithelial mesenchymal transition progression through the miR-152-3p/JAK1 pathway
    Hong Li
    Yu Wu
    Runmei Wang
    Junmei Guo
    Qin Yu
    Lihe Zhang
    Haiping Zhao
    Hao Yang
    Genes & Genomics, 2022, 44 : 133 - 144
  • [22] LncSNHG3 promotes hepatocellular carcinoma epithelial mesenchymal transition progression through the miR-152-3p/JAK1 pathway
    Li, Hong
    Wu, Yu
    Wang, Runmei
    Guo, Junmei
    Yu, Qin
    Zhang, Lihe
    Zhao, Haiping
    Yang, Hao
    GENES & GENOMICS, 2022, 44 (01) : 133 - 144
  • [23] USP5 promotes epithelial-mesenchymal transition by stabilizing SLUG in hepatocellular carcinoma
    Meng, Jing
    Ai, Xiaoyu
    Lei, Yueyang
    Zhong, Weilong
    Qian, Baoxin
    Qiao, Kailiang
    Wang, Xiaorui
    Zhou, Bijiao
    Wang, Hongzhi
    Huai, Longcong
    Zhang, Xiaoyun
    Han, Jingxia
    Xue, Yinyin
    Liang, Yuan
    Zhou, Honggang
    Chen, Shuang
    Sun, Tao
    Yang, Cheng
    THERANOSTICS, 2019, 9 (02): : 573 - 587
  • [24] RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-κB-mediated epithelial-mesenchymal transition
    Zhang, Yang
    Ni, Weixing
    Qin, Lei
    AGING-US, 2021, 13 (17): : 21283 - 21293
  • [25] Decreased BIRC5-206 promotes epithelial-mesenchymal transition in nasopharyngeal carcinoma through sponging miR-145-5p
    Xu, Weihua
    Hu, Junjie
    Ma, Zhichao
    Feng, Wanyi
    Gong, Wei
    Fu, Shengmiao
    Chen, Xinping
    OPEN MEDICINE, 2024, 19 (01):
  • [26] RETRACTED: The long noncoding RNA AK002107 negatively modulates miR-140-5p and targets TGFBR1 to induce epithelial-mesenchymal transition in hepatocellular carcinoma (Retracted Article)
    Tang, Yun-Hua
    He, Guo-Lin
    Huang, Shan-Zhou
    Zhong, Ke-Bo
    Liao, Hui
    Cai, Lei
    Gao, Yi
    Peng, Zhen-Wei
    Fu, Shun-Jun
    MOLECULAR ONCOLOGY, 2019, 13 (05) : 1296 - 1310
  • [27] Glypican-3 promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through ERK signaling pathway
    Wu, Yongle
    Liu, Hui
    Weng, Honglei
    Zhang, Xin
    Li, Peng
    Fan, Chun-Lei
    Li, Bing
    Dong, Pei-Ling
    Li, Lei
    Dooley, Steven
    Ding, Hui-Guo
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2015, 46 (03) : 1275 - 1285
  • [28] Glutamine synthetase promotes tumor invasion in hepatocellular carcinoma through mediating epithelial-mesenchymal transition
    Liu, Peng
    Lu, Di
    Al-ameri, Abdulahad
    Wei, Xuyong
    Ling, Sunbin
    Li, Jie
    Zhu, Hai
    Xie, Haiyang
    Zhu, Liming
    Zheng, Shusen
    Xu, Xiao
    HEPATOLOGY RESEARCH, 2020, 50 (02) : 246 - 257
  • [29] Overexpression of SIRT1 promotes metastasis through epithelial-mesenchymal transition in hepatocellular carcinoma
    Hao, Chong
    Zhu, Peng-Xi
    Yang, Xue
    Han, Zhi-Peng
    Jiang, Jing-Hua
    Zong, Chen
    Zhang, Xu-Guang
    Liu, Wen-Ting
    Zhao, Qiu-Dong
    Fan, Ting-Ting
    Zhang, Li
    Wei, Li-Xin
    BMC CANCER, 2014, 14
  • [30] Overexpression of SIRT1 promotes metastasis through epithelial-mesenchymal transition in hepatocellular carcinoma
    Chong Hao
    Peng-Xi Zhu
    Xue Yang
    Zhi-Peng Han
    Jing-Hua Jiang
    Chen Zong
    Xu-Guang Zhang
    Wen-Ting Liu
    Qiu-Dong Zhao
    Ting-Ting Fan
    Li Zhang
    Li-Xin Wei
    BMC Cancer, 14